Skip to main content
. Author manuscript; available in PMC: 2017 Dec 21.
Published in final edited form as: Neuron. 2016 Dec 8;92(6):1238–1251. doi: 10.1016/j.neuron.2016.11.012

Figure 2. Enhancing eIF2α signaling corrects ΔE Torsin1a mislocalization.

Figure 2

(A) eIF2α signaling pathway diagram. Actions of compounds tested in panels (C) through (F) are indicated in blue.

(B) WGS results relevant to the eIF2α pathway. Blue – gene hits bioinformatically implicating the eIF2α pathway. Red – eIF2α kinases. Dashed lines indicate +/−3SD from mean.

(C-H) Left – Effects of the indicated compounds on Torsin1a localization (black), cell count (grey), and EGFP-Torsin1a expression (green) in the ΔE (C-E, G, H) or WT (F) assay cell lines. Percent Selected Cells was normalized such that vehicle-treated ΔE cells = 100 and vehicle-treated WT cells = 0. GFP Intensity and Cell Count were normalized such that vehicle-treated ΔE cells = 100. Right – Representative images from the respective treatments. Scale bars = 20 μm. n = 4 per compound dose for dose response data or 24 for untreated control data (used for normalization). All data are presented as means ± S.E.M.